Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort studyResearch Article Published on 2020-11-162022-10-28 Journal: BMC Nephrology [Category] COVID-19, SARS, [키워드] Abstract Acute kidney injury Administered administration AKI anticoagulation Care citrate cohort study collected data coronavirus disease Course COVID-19 COVID-19 patient Critical care Critically ill Critically ill patient dialysis effective Efficiency Emerging communicable diseases event Germany Health Hemodialysis high risk hypercoagulability intensive care unit LMWH low molecular weight maintain outcome Patient patients Prevent receiving reduce regimen renal replacement therapy Result RRT Safe SARS-CoV-2 significantly supplementary material sustained systemic anticoagulation the disease therapeutic Thromboembolic events Treatment unfractionated heparin was performed [DOI] 10.1186/s12882-020-02150-8 PMC 바로가기 [Article Type] Research Article
D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review정맥 혈전 색전증이 의심되는 COVID-19 환자의 D-이량체, 피브리노겐 및 IL-6: 내러티브 검토Review Published on 2020-11-132022-09-10 Journal: Vascular Health and Risk Management [Category] MERS, 바이오마커, [키워드] activated acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus aPTT ARDS China Coagulation Coagulopathy coronavirus coronavirus disease Coronavirus disease 2019 cough COVID-19 COVID-19 patient COVID-19 patients critical COVID-19 patient critical COVID-19 patients Critically ill critically ill patients Cytokine storm D-dimer D-dimers Deep vein Deep vein thrombosis Degradation develop Disease progression Disseminated intravascular coagulation District DVT early diagnosis elevated Evidence evidence of Fever FIBRIN fibrin degradation products fibrinogen Fibrinogen levels global pandemic Health Organization heparin highlighting hyperactivity IL-6 include interleukin interleukin-6 intravascular coagulation Laboratory parameters lethargy LMWH low molecular weight low molecular weight heparin manifestation Mortality multiple organ failure narrative Organ failure Platelets Prognostic factor Prophylaxis prothrombin Prothrombin time Pulmonary embolism reducing respiratory respiratory distress review risk SARS-CoV-2 Seafood severe acute respiratory syndrome Coronavirus shown stages Suspected syndrome THROMBOPLASTIN Thromboprophylaxis thrombosis Thrombosis prophylaxis thrombotic thrombotic event Thrombotic events Treatment upper respiratory symptom upper respiratory symptoms Venous Thromboembolism VTE West WHO World Health Organization [DOI] 10.2147/VHRM.S280962 PMC 바로가기 [Article Type] Review
Biomarkers of Hypercoagulability and Endothelial Cell Activation in Patients with Severe COVID-19 Admitted at the Intensive Care Unit. the Roadmap-COVID-19 Prospective Observational StudyConference abstract Published on 2020-11-042022-10-05 Journal: Blood [Category] 바이오마커, [키워드] Activation acute respiratory distress acute respiratory syndrome Algorithm Antithrombotic AP-HP ARDS Biomarker Blood coagulation calculated cause cellular change characterized clinically clotting factor Cluster Coagulation cohort study complications consecutive patient Control control group controls coronavirus coronavirus disease COVID-19 D-dimer decrease disease download effect of treatment endothelial Endothelial cell Endothelial dysfunction enrolled evaluate evaluated excessive inflammation expressing fibrinogen FVIII healthy individual Heparanase Hospitalized hypercoagulability ICU ICU admission ICU patient IL-6 IL-6 level increase indicate indicated inflammatory reaction Inhaled inhibitor intensive care unit intrinsic life-threatening LMWH management mandatory Microparticle moderate modify molecular weight monomer MRI Multisystem organ failure outcome Paris pathway Patient patients patients hospitalized patients with COVID-19 peak platelet activation Pneumonia Prospective Prospective Study Protein protein S ranged Ratio Respiratory failure Result SARS-CoV-2 SARS-COV-2 infection severe COVID-19 shown significant decrease significantly STABLE syndrome table TFPI the mean the patient thrombin Thromboprophylaxis university von Willebrand factor were assessed with COVID-19 [DOI] 10.1182/blood-2020-140275 [Article Type] Conference abstract
Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical InvestigationCOVID-19 동시 감염 환자의 사망률 감소에 대한 폐렴구균 요인 검사 효과: 임상 조사Article Published on 2020-10-292022-10-30 Journal: Medicina [Category] COVID-19, MERS, SARS, 폐렴구균 감염증, [키워드] acute respiratory syndrome added Analysis Antibiotic therapy antibodies Antigen Azithromycin bacterial infection 2 ceftriaxone chi-square test clinical Co-infection Cohort coronavirus disease COVID-19 COVID-19 outbreak COVID-19 patient Critical decreasing detect early diagnosis Effectiveness Final group hospital Hospital stay Hospitalization Hospitalized Hydroxychloroquine investigation Italy levofloxacin LMWH Lopinavir/ritonavir material Mortality mortality rate not differ not significant Patient patients pneumococcal pneumococcal infection Pneumonia positive Prognosis protocols reduction in mortality SARS-CoV-2 screened Streptococcus Streptococcus pneumoniae survival survival analysis Testing Treatment Trial urinary [DOI] 10.3390/medicina56110572 PMC 바로가기 [Article Type] Article
Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory DiseaseOriginal Article Published on 2020-10-232022-10-29 Journal: TH Open: Companion Journal to Thrombosis and Haemostasis [Category] COVID-19, [키워드] acute respiratory distress anticoagulation apixaban Atrial fibrillation benefit bleeding bleeding event coagulation parameter Coagulation parameters Coagulopathy COVID-19 death Direct disease DOACs Efficacy evaluate evaluated follow-up period ICU ICU patient Ill incidence initiated intensive care LMWH low molecular weight major bleeding event material mechanical ventilation morbidity and mortality Mortality novel coronavirus disease obese oral anticoagulant Patient Prophylaxis remained renal dysfunction renal replacement therapy required respiratory Respiratory disease Result retrospective cohort study Safe Safety SARS-CoV-2 seeking severe COVID-19 severe COVID-19 disease study period subsequent syndrome thromboembolic disease Thromboembolic events thrombosis treated Treatment Trial unfractionated heparin Venous Thromboembolism VTE [DOI] 10.1055/s-0040-1720962 PMC 바로가기 [Article Type] Original Article
The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID‐19 Patients: A Retrospective Cohort Study중증 COVID-19 환자에서 사이토카인 폭풍을 완화하기 위한 저분자량 헤파린의 가능성: 후향적 코호트 연구Article Published on 2020-10-152022-09-25 Journal: Clinical and translational science [Category] MERS, SARS, 진단, 치료제, [키워드] “cytokine storm” attenuate change changes in clinical study complementary control group coronavirus disease COVID‐19 D‐dimer Disease progression drug electronic medical record evaluate the effect fibrinogen degradation product global pandemic heparin Hospitalized IL‐6 Laboratory LMWH low molecular weight lymphocyte Patient performed Potential reduced Retrospective analysis SARS‐CoV‐2 Science significantly storm subsequent Support technology therapeutic drug treated Treatment Union Hospital university virus weight World Health Organization [DOI] 10.1111/cts.12880 PMC 바로가기 [Article Type] Article
Increased Plasma Heparanase Activity in COVID-19 PatientsImmunology Published on 2020-10-062022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, [키워드] activity applied clinically contribute COVID-19 COVID-19 patient COVID-19 patients creatinine disease severity elevated endothelial Endothelial dysfunction enzyme glycocalyx damage healthy control Heparanase heparin Hypothesis Increased Inflammation inhibited inhibitor intensive care lactate dehydrogenase LMWH LMWH (low molecular weight heparin) low molecular weight molecular weight non-ICU patient pathogenesis of COVID-19 plasma Prophylactic reduced report significantly Therapeutic treatment vascular leakage were measured [DOI] 10.3389/fimmu.2020.575047 PMC 바로가기 [Article Type] Immunology
Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after studyCOVID-19가 있는 중환자 중환자실 환자에서 개별화된 혈전 예방 프로토콜 시행의 영향: 종단적으로 통제된 전후 연구Article Published on 2020-10-012022-09-11 Journal: Thrombosis research [Category] 바이오마커, [키워드] Acute kidney injury admitted to ICU all consecutive adult patients Clinical outcome confirmation confounding variables Continuous Continuous renal replacement therapy coronavirus disease Coronavirus disease 2019 correction COVID-19 COVID-19 patient COVID-19 pneumonia Critically ill Critically ill patient critically ill patients CRRT cumulative cumulative incidence cumulative risk dropped DVT Endpoint evaluate the effect focus Future ICU patient Impact implementation IMPROVE incidence include Intervention LMWH mechanism Mortality Multiple outcome Patient Pneumonia primary endpoint protocol Randomized reduce mortality reduced Registration registration number remained renal renal replacement therapy replacement therapy Research risk secondary Secondary outcomes significantly significantly higher Thromboembolism Thromboprophylaxis two groups Venous Thromboembolism VTE was used [DOI] 10.1016/j.thromres.2020.07.038 PMC 바로가기 [Article Type] Article
Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative reviewReview Published on 2020-09-162022-10-28 Journal: Annals of Intensive Care [Category] COVID-19, [키워드] Activation Admission anticoagulation bleeding event Blood cells Comorbidities complement coronavirus COVID-19 Critically ill patient cytokine release decision described dose Endothelial dysfunction Epidemiology event explained Factors hospital hospital discharge hospitalized patient ICU implication incidence intensive care Interaction life-threatening LMWH low molecular weight management mechanisms pathologic consequence pathophysiologic Patient patients with PE procoagulant Prophylactic Prophylaxis Pulmonary embolism reduced risk reported risk risk factor SARS-CoV-2 Selection therapeutic Thromboprophylaxis unfractionated heparin Venous Thromboembolism VTE VTE risk [DOI] 10.1186/s13613-020-00741-0 PMC 바로가기 [Article Type] Review
Acute Splenic Artery Thrombosis and Infarction Associated with COVID-19 DiseaseCase Report Published on 2020-09-042022-10-31 Journal: Case Reports in Critical Care [Category] COVID-19, [키워드] acute respiratory syndrome Anticoagulant anticoagulation Artery caused coronavirus COVID-19 discharged home disease global pandemic hypercoagulable hypoxemic intermediate dose LMWH Mild Multiple Patient Prophylaxis recommendation reported Respiratory failure SARS-CoV-2 Severe case severe pneumonia Splenic Splenic infarction symptomatic symptoms of COVID-19 thrombosis treated upper respiratory symptom widespread with COVID-19 Wuhan, China [DOI] 10.1155/2020/8880143 PMC 바로가기 [Article Type] Case Report